Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Celgene Corporation (CELG)’s New Acquisition — of Celgene

Page 1 of 2

Celgene Corporation (NASDAQ:CELG) announced on Wednesday a $600 million deal to buy a stake in a growing biotech with several successful products on the market and a strong pipeline. Who is this new acquisition? The lucky company is none other than… Celgene itself.

The company has already repurchased over $5 billion of its stock over the past four years. Just in the past two months, Celgene bought back $385 million worth of shares. Is this a smart move for the company? Let’s take a look.

Celgene Corporation (NASDAQ:CELG)Alternatives
Thanks largely to its incredible success with Revlimid, Celgene currently sits on top of a cash stockpile of $3.9 billion. That money isn’t making too much of a return just sitting idly, so it makes sense for Celgene to consider alternatives. The major options for the company include giving some of the money back to shareholders as a dividend, buying another company, or repurchasing its own shares.

Like many investors, I love dividends. However, I can understand Celgene’s reluctance to issue a dividend right now. Once you’ve started paying dividends, you can’t stop — at least, not without having your stock clobbered. And paying dividends gives the impression to many that a company can’t find a better way to generate returns with the money. I don’t think that’s the case for Celgene.

So, why not buy an up-and-coming biotech? With the just-announced buyback, Celgene will spend nearly $1 billion this year alone. There are plenty of companies specializing in cancer drugs as Celgene does that could be bought for that amount or close to it.

Dendreon Corporation (NASDAQ:DNDN), for example, has prostate cancer drug Provenge on the market and several other drugs in development. The company’s current market cap is around $900 million. Exelixis, Inc. (NASDAQ:EXEL) has a late-stage trial under way for thyroid cancer drug cabozantinib, as well as other studies for the drug targeting other forms of cancer. Its market cap stands at $827 million.

An even more affordable buy would be Clovis Oncology Inc (NASDAQ:CLVS), with a market cap just below $500 million. Clovis has several trials under way for cancer treatments, most notably CO-101 targeting pancreatic cancer.

One could argue the pros and cons for an acquisition of these or a number of other small biotechs. However, none of them can boast of the current earnings power that Celgene can. My view is that if Celgene somehow spun off only its pipeline drugs into a separate company, the newly formed company would be a better buy than any of these other biotechs. That isn’t saying these companies don’t have plenty of merits. Celgene’s potential is just better.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!